Efficacy and safety of capmatinib plus spartalizumab in treatment-naive patients with advanced NSCLC harboring MET exon 14 skipping mutation

被引：5
|
作者：
Wolf, J. [1 ]
Heist, R. [2 ]
Kim, T. M. [3 ]
Nishio, M. [4 ]
Dooms, C. [5 ]
Kanthala, R. R. [6 ]
Leo, E. [7 ]
Giorgetti, E. [7 ]
Wang, Y. [8 ]
Mardjuadi, F. I. [8 ]
Cortot, A. [9 ]
机构：
[1] Univ Klinikum Koln AoR, Dept Internal Med 1, Ctr Integrated Oncol, Cologne, Germany
[2] Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA
[3] Seoul Natl Univ, Coll Med, Dept Internal Med, Yeongeon Med Campus, Seoul, South Korea
[4] JFCR, Canc Inst Hosp, Dept Thorac Med Oncol, Koto Ku, Tokyo, Japan
[5] Univ Hosp Leuven, UZ Leuven, Dept Resp Dis, Campus Gasthuisberg, Leuven, Belgium
[6] Novartis Healthcare Pvt Ltd, GDO DO Stat Programming, Hyderabad, Telangana, India
[7] Novartis Pharma AG, Oncol, Basel, Switzerland
[8] Novartis Inst BioMed Res Co Ltd, Oncol, Shanghai, Peoples R China
[9] Univ Lille, CHU Lille, Thorac Oncol Dept,Inst Pasteur Lille, CNRS,Inserm,UMR9020,UMR S 1277 Canther, Lille, France
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1120
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
994P
引用
收藏
页码：S1007 / S1008
页数：2
相关论文
共 50 条
  • [1] Capmatinib in advanced NSCLC for previously treated patients with MET exon 14 skipping mutation
    Basse, Clemence
    Blancard, Lucie Regaldo-Saint
    BULLETIN DU CANCER, 2023, 110 (09)
  • [2] Efficacy and tolerability of capmatinib in a very elderly patient with metastatic NSCLC harboring a MET exon 14 mutation
    Conci, Nicole
    Marchiori, Virginia
    Federico, Alessandro Di
    Giglio, Andrea De
    Sperandi, Francesca
    Melotti, Barbara
    Gelsomino, Francesco
    PERSONALIZED MEDICINE, 2024, 21 (04) : 205 - 209
  • [3] FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations
    Mathieu, Luckson N.
    Larkins, Erin
    Akinboro, Oladimeji
    Roy, Pourab
    Amatya, Anup K.
    Fiero, Mallorie H.
    Mishra-Kalyani, Pallavi S.
    Helms, Whitney S.
    Myers, Claire E.
    Skinner, Amy M.
    Aungst, Stephanie
    Jin, Runyan
    Zhao, Hong
    Xia, Huiming
    Zirkelbach, Jeanne Fourie
    Bi, Youwei
    Li, Yangbing
    Liu, Jiang
    Grimstein, Manuela
    Zhang, Xinyuan
    Woods, Stacie
    Reece, Kelie
    Abukhdeir, Abdelrahmman M.
    Ghosh, Soma
    Philip, Reena
    Tang, Shenghui
    Goldberg, Kirsten B.
    Pazdur, Richard
    Beaver, Julia A.
    Singh, Harpreet
    CLINICAL CANCER RESEARCH, 2022, 28 (02) : 249 - 254
  • [4] Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION
    Kato, Terufumi
    Yang, James Chih-Hsin
    Ahn, Myung-Ju
    Sakai, Hiroshi
    Morise, Masahiro
    Chen, Yuh-Min
    Han, Ji-Youn
    Yang, Jin-Ji
    Zhao, Jun
    Hsia, Te-Chun
    Berghoff, Karin
    Bruns, Rolf
    Vioix, Helene
    Lang, Simone
    Johne, Andreas
    Le, Xiuning
    Paik, Paul K.
    BRITISH JOURNAL OF CANCER, 2024, 130 (10) : 1679 - 1686
  • [5] Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION
    Terufumi Kato
    James Chih-Hsin Yang
    Myung-Ju Ahn
    Hiroshi Sakai
    Masahiro Morise
    Yuh-Min Chen
    Ji-Youn Han
    Jin-Ji Yang
    Jun Zhao
    Te-Chun Hsia
    Karin Berghoff
    Rolf Bruns
    Helene Vioix
    Simone Lang
    Andreas Johne
    Xiuning Le
    Paul K. Paik
    British Journal of Cancer, 2024, 130 : 1679 - 1686
  • [6] Tepotinib efficacy and safety in patients with MET exon 14 (METex14) skipping NSCLC
    Garassino, Marina C.
    Le, Xiuning
    Iam, Wade T.
    Felip, Enriqueta
    Sakai, Hiroshi
    Veillon, Remi
    Smit, Egbert F.
    Mazieres, Julien
    Raskin, Jo
    Cortot, Alexis B.
    Berghoff, Karin
    Bruns, Rolf
    Otto, Gordon
    Paik, Paul K.
    CANCER RESEARCH, 2022, 82 (12)
  • [7] Efficacy and safety of dacomitinib in treatment-naive patients with advanced NSCLC harboring uncommon EGFR mutations
    Wu, L.
    Pu, X.
    Zhou, Y.
    Kong, Y.
    Chen, B.
    Yang, A.
    Li, J.
    Li, K.
    Xu, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1695 - S1695
  • [8] Tepotinib in patients with MET exon 14 skipping NSCLC: Efficacy and safety by line of therapy
    Griesinger, F.
    Felip, E.
    Smit, E. F.
    Veillon, R.
    Raskin, J.
    Thomas, M.
    Conte, P.
    Kowalski, D.
    Paz-Ares, L.
    Garcia Ledo, G.
    de Marinis, F.
    Scherz, A.
    Berghoff, K.
    Bruns, R.
    Otto, G.
    Paik, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S40 - S41
  • [9] Rapid Disease Progression in a Patient with Advanced NSCLC Harboring a Germline MET Exon 14 Skipping Mutation: A Case Report
    Jiao, Yang
    Fang, Chen
    Yang, Yuchen
    Shao, Lin
    Huang, Yi
    Sun, Qinying
    Dong, Yuchao
    ONCOTARGETS AND THERAPY, 2021, 14 : 2417 - 2421
  • [10] Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
    Liu, Li
    Kalyani, Farhin Shaheed
    Yang, Haiyan
    Zhou, Chunhua
    Xiong, Yi
    Zhu, Songlin
    Yang, Nong
    Qu, Jingjing
    FRONTIERS IN ONCOLOGY, 2021, 11
12345